Nyrada, Inc. · ASX:NYR
Nyrada — Shareholder Meeting (November 2020)
17 slides from Nyrada's shareholder meeting presentation, Nov 19, 2020
Slide 1: Presentation to Annual General Meeting of Shareholders
Improve Lives, Offer Hope For personal use only New Therapies for Cardiovascular & Neurological Diseases Presentation to Annual General Meeting of Shareholders James Bonnar Chief Executive Officer Sydney NSW 19 November 2020 ASX:NYR 1
Slide 2: Important Notice & Disclaimer
Important Notice & Disclaimer For personal use only This presentation has been prepared by Nyrada Inc (NYR or the Company). It should not Although the Company believes that the expectations reflected in the forward looking be considered as an offer or invitation to subscribe for, or purchase any sha
Slide 3: Nyrada Summary
Nyrada Summary For personal use only Drug discoverer Diverse product portfolio, significant therapeutic and commercial potential, near term milestones. and early stage developer High calibre Board and Scientific Advisory Board, including highly connected industry and research experts in the US, Euro
Slide 4: Nyrada Inc Vision and Mission
Nyrada Inc For personal use only Vision We can improve lives and offer hope through innovation Deliver a single, cost-competitive and convenient cholesterol lowering treatment so that anyone can achieve a safe cholesterol level (reduce heart attack and stroke) Deliver the first-ever treatment to pre
Slide 5: Nyrada Programs and Strategy
Nyrada Programs and Strategy For personal use only Cholesterol lowering Small molecule PCSK9 inhibitor to lower LDL-cholesterol that can be administered as a pill that can be combined with a statin Value inflection point in 2-3 years Brain injury Intravenous drug administered to patients admitted to
Slide 6: Why is Lowering LDL Cholesterol Important?
Why is Lowering LDL Cholesterol Important? For personal use only High LDL Cholesterol leading cause of cardiovascular disease Cardiovascular disease responsible for 1 in 4 deaths 6
Slide 7: Statin Drugs
Statin Drugs For personal use only 19.4 million 27.4 million Unable to achieve US adults with elevated LDL-C target despite LDL-C are taking a statin Low cost taking statin therapy Suboptimal efficacy US$19B Statin sales in 2017 Wong ND et al. Prevalence of the American College of Cardiology/America
Slide 8: Current PCSK9 Inhibitors
Current PCSK9 Inhibitors For personal use only PCSK9 LDL receptor degradation Effective and safe Fewer receptors high LDL cholesterol Synergy with statins Expensive US$5,800 per year Inconvenient (2-4 weekly injection) PCSK9 inhibitor low LDL cholesterol US$950M Repatha & Praluent sales in 2019 Stat
Slide 9: Encouraging Results in Cholesterol Lowering
Encouraging Results in Cholesterol Lowering For personal use only Equivalence demonstrated between Nyrada’s NYX-PCSK9i and the two FDA approved monoclonal PCSK9 antibody drugs Repatha™ (Amgen) and Praluent™ (Sanofi/Regeneron) - Statin + Statin % LDLR retention % LDLR retention No drug 51% 64% NYX-PC
Slide 10: Improving Quality of Life for Brain Injury patients
Improving Quality of Life for Brain Injury patients For personal use only Each year in the US: Neurology / physical rehabilitation only existing - High mortality - 2.8 million people sustain therapies - Severe life-long disability a traumatic brain injury (TBI) - One drug class for stroke - High ong
Slide 11: Nyrada Brain Injury Solution
Nyrada Brain Injury Solution For personal use only Treatment for secondary brain injury following Stroke or TBI - Prevent cell death - Attenuate damaged brain volume - Improve survivability, limit disability, improve quality of life Primary Secondary Disability Injury Injury Level Hours Days Weeks M
Slide 12: Brain Injury Program Continues to Advance
Brain Injury Program Continues to Advance For personal use only Two drug candidates achieved therapeutic levels in a preclinical pharmacokinetic study Drug levels in the brain were assessed via a 6-hour continuous intravenous infusion (preferred route for moderate-severe TBI and Stroke) Candidates w
Slide 13: Preclinical Pharmacokinetic Rat Study
Preclinical Pharmacokinetic Rat Study For personal use only • Drug candidate NYX-1010 maintained at therapeutic levels in the brain in PK rat study (intravenous dosing) • Demonstrates delivery via preferred route for patients suffering from stroke and moderate-severe TBI with desired PK profiles for
Slide 14: FY20 Financials & Corporate Achievements
FY20 Financials & Corporate Achievements For personal use only FY20 FY19 • Successful listing on the ASX and fully subscribed IPO raising $8.5 million Revenue and other income $1,125,414 $505,697 R&D and employee expenses $2,742,992 $2,439,343 • A$1.075 million cash rebate from the Australian Federa
Slide 15: Since April 2020 >60% of spend related to R&D activities
Since April 2020 >60% of spend related to R&D activities For personal use only $1,600,000 $1,400,000 $1,200,000 * The December 2019 and March $1,000,000 2020 quarters admin and AUD corporate expenditure was $ $800,000 higher due to the costs associated with successfully $600,000 listing on the ASX.
Slide 16: Key Milestones and Anticipated Newsflow
Key Milestones and Anticipated Newsflow For personal use only H2 H1 H2 H1 Cholesterol Lowering Program 2020 2021 2021 2022 Clinical candidate selection: • In vivo efficacy study of NYX-PCSK9i (Q4 2020) • X-ray crystal structure study (Q1 2021) • In vitro lead optimisation - ongoing • Preclinical saf
Slide 17: Corporate Snapshot
Corporate Snapshot For personal use only Market capitalisation $21M (as at 18 November 2020) Share price $0.195 Neuroprotection Animation (as at 18 November 2020) @nyrada_inc CDIs free float 76,072,869 CDIs 12 months escrow 205,000 @nyrada_inc Cholesterol-Lowering Animation CDIs 24 months escrow 33,